Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,097 Million (Small Cap)
20.00
NA
7.55%
-0.20
7.02%
1.82
Revenue and Profits:
Net Sales:
569 Million
(Quarterly Results - Sep 2025)
Net Profit:
23 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.81%
0%
-3.81%
6 Months
-2.77%
0%
-2.77%
1 Year
1.61%
0%
1.61%
2 Years
3.1%
0%
3.1%
3 Years
-8.93%
0%
-8.93%
4 Years
-27.27%
0%
-27.27%
5 Years
27.68%
0%
27.68%
Yabao Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.21%
EBIT Growth (5y)
5.75%
EBIT to Interest (avg)
20.35
Debt to EBITDA (avg)
0.20
Net Debt to Equity (avg)
-0.19
Sales to Capital Employed (avg)
0.87
Tax Ratio
22.17%
Dividend Payout Ratio
88.24%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.87%
ROE (avg)
5.84%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.63
EV to EBIT
15.65
EV to EBITDA
10.22
EV to Capital Employed
1.77
EV to Sales
1.72
PEG Ratio
1.08
Dividend Yield
5.08%
ROCE (Latest)
11.28%
ROE (Latest)
8.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
569.30
524.90
8.46%
Operating Profit (PBDIT) excl Other Income
36.60
107.40
-65.92%
Interest
0.00
0.60
-100.00%
Exceptional Items
0.70
-0.00
Consolidate Net Profit
23.30
69.10
-66.28%
Operating Profit Margin (Excl OI)
64.30%
140.80%
-7.65%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 8.46% vs -14.58% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -66.28% vs -34.87% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,668.50
2,890.20
-7.67%
Operating Profit (PBDIT) excl Other Income
424.30
448.60
-5.42%
Interest
5.70
12.70
-55.12%
Exceptional Items
-25.90
-84.30
69.28%
Consolidate Net Profit
223.90
179.90
24.46%
Operating Profit Margin (Excl OI)
106.10%
100.00%
0.61%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -7.67% vs 7.09% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 24.46% vs 71.99% in Dec 2023
About Yabao Pharmaceutical Group Co., Ltd. 
Yabao Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






